Drug Profile

Research programme: pain therapeutics - Axxam

Alternative Names: BKR1 antagonist - Axxam; CB2 agonist - Axxam; Nav 1.7 blocker - Axxam; TRPM8 blocker - Axxam

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Axxam; Newron Pharmaceuticals; Primm srl; University of Milan Bicocca
Developer Axxam; Newron Pharmaceuticals
Class
Mechanism of Action Bradykinin B1 receptor antagonists; Cannabinoid receptor CB2 agonists; Nav1.7 voltage-gated sodium channel inhibitors; Purinergic P2X7 receptor antagonists; TRPM8 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

04 Nov 2017 No recent reports of development identified for research development in Pain in Italy
02 Feb 2011 Early research is ongoing in Italy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com